Anticancer combination of artemisinin-based drugs and other chemotherapeutic agentsThe present invention relates to combinations between artemisinin-based potent anti-malarial agents, selected from the group consisting of ART, DHA and ARM, and a further chemotherapeutic drug selected from the group consisting of a camptothecin derivative, or a PARP-1 inhibitor, or an intercalating DNA agent, or an alkylating agent. Such combinations, showed medium to strong synergism in various models of cancer, in particular in NSCL.Chemotherpeutic compositions, it is made up of agents (a) and chemotherapeutant (b), and wherein agents (a) is selected from the group that art, dha and arm form; and chemotherapeutant (b) is selected from by the following group of forming: camptothecin derivative; the parp-1 inhibitor; dna intercalator and alkylating agent; said camptothecin derivative itself is selected from the group of being made up of following: 7-methoxyimino methyl camptothecine, 7-methoxyimino methyl isophthalic acid 0-hydroxy camptothecin, 7-(tertbutyloxycarbonyl-2-propoxyl group)-iminomethyl camptothecin, 7-ethoxy imino methyl camptothecine, 7-isopropoxy-iminomethyl camptothecin, 7-(2-methyl butoxy)-iminomethyl camptothecin, 7-are t-butoxyiminomethylcamconjugated, 7-tert-butoxy iminomethyl-10-hydroxycamptothecine, 7-tert-butoxy iminomethyl-10-methoxycamptothecine, 7-(4-hydroxyl butoxy)-iminomethyl camptothecin, 7-triphenyl-methoxyimino methyl camptothecine, 7-carboxyl methoxyimino methyl camptothecine, 7-(2-is amino)-ethoxy imino methyl camptothecine, 7-(2-n; the n-dimethylamino)-and ethoxy imino methyl camptothecine, 7-allyloxy iminomethyl camptothecin, 7-cyclohexyl-oxygen base iminomethyl camptothecin, 7-cyclohexyl methoxyimino methyl camptothecine, 7-ring octyloxy iminomethyl camptothecin, 7-ring octyl group methoxyimino methyl camptothecine, 7-benzyloxy-iminomethyl camptothecin, 7-[(1-benzyloxy imino group)-2-phenylethyl] camptothecine, 7-(1-benzyloxy imino group)-ethyl-camptothecin, 7-phenoxy group-iminomethyl camptothecin, 7-(1-tert-butoxy imino group)-ethyl-camptothecin, 7-be right-nitrobenzyl-oxygen base iminomethyl camptothecin, 7-be right-methyl benzyloxy iminomethyl camptothecin, 7-five fluoro-benzyloxy iminomethyl camptothecins, 7-be right-phenyl benzyloxy iminomethyl camptothecin, 7-[2-(2,4 difluorobenzene base)-ethyoxyl] iminomethyl camptothecin, 7-(4-tert-butyl group benzyloxy)-iminomethyl camptothecin, 7-(1-buddha's warrior attendant alkoxyl)-iminomethyl camptothecin, 7-(1-adamantyl methoxyl group)-iminomethyl camptothecin, 7-(2-naphthoxy)-iminomethyl camptothecin, 7-(9-anthryl methoxyl group)-iminomethyl camptothecin, 7-epoxy ethyl methoxyimino methyl camptothecine, 7-(6-uracil base)-methoxyl group-iminomethyl camptothecin, 7-[2-(1-uracil base)-ethyoxyl]-iminomethyl camptothecin, 7-(4-pyridine radicals)-methoxyimino methyl camptothecine, 7-(2-thienyl)-methoxyimino methyl camptothecine, 7-[(n-methyl)-4-piperidyl]-methoxyimino methyl camptothecine, 7-[2-(4-morpholinyl)-ethyoxyl]-iminomethyl camptothecin, 7-(benzoyloxy iminomethyl)-camptothecine, 7-[(1-oxyimino)-2-phenylethyl]-camptothecine, 7-tert-butoxy-iminomethyl camptothecin n-oxide, 7-methoxyimino methyl camptothecin n-oxide, irinotecan and active metabolite sn-38 thereof; wherein in said composition, each composition (a) reaches and (b) is separated from each other preparation or is formulated as single dosage form.
아르테미시닌계 약물 및 다른 화학요법제의 항암 조합물본 발명은 ART, DHA 및 ARM으로 이루어진 그룹으로부터 선택된 아르테미시닌계 강력한 항말라리아제, 및 캄프토테신 유도체, 또는 PARP-1 억제제, 또는 삽입성 DNA 제제, 또는 알킬화제로 이루어진 그룹으로부터 선택된 추가 화학요법 약물 사이의 조합물에 관한 것이다. 그와 같은 조합물은 다양한 모델의 암, 특히 NSCL에서 강한 상승작용에 대한 매개체를 보여주었다.ART, DHA 및 ARM으로 이루어진 그룹으로부터 선택된 약제 (a); 및 7-메톡시이미노메틸캄프토테신, 7-메톡시이미노메틸-10-하이드록시-캄프토테신, 7-(ter-부톡시카보닐-2-프로폭시)-이미노메틸캄프토테신, 7-에톡시이미노메틸캄프토테신, 7-이소프로폭시-이미노메틸캄프토테신, 7-(2-메틸부톡시)-이미노메틸캄프토테신, 7-t-부톡시이미노메틸캄프토테신, 7-t-부톡시이미노메틸-10-하이드록시캄프토테신, 7-t-부톡시이미노메틸-10-메톡시캄프토테신, 7-(4-하이드록시부톡시)-이미노메틸캄프토테신, 7-트리페닐-메톡시이미노메틸캄프토테신, 7-카복시메톡시이미노메틸-캄프토테신, 7-(2-아미노)-에톡시이미노메틸-캄프토테신, 7-(2-N,N-디메틸아미노)-에톡시이미노메틸캄프토테신, 7-알릴옥시이미노메틸-캄프토테신, 7-사이클로헥실-옥시이미노메틸캄프토테신, 7-사이클로헥실메톡시-이미노메틸캄프토테신, 7-사이클로옥틸옥시이미노메틸-캄프토테신, 7-사이클로옥틸메톡시이미노메틸-캄프토테신, 7-벤질옥시-이미노메틸-캄프토테신, 7-[(1-벤질옥시이미노)-2-페닐에틸]캄프토테신, 7-(1-벤질옥시이미노)-에틸캄프토테신, 7-페녹시-이미노메틸캄프토테신, 7-(1-t-부톡시이미노)-에틸캄프토테신, 7-p-니트로벤질-옥시이미노메틸-캄프토테신, 7-p-메틸벤질옥시이미노메틸캄프토테신, 7-펜타플루오로-벤질옥시이미노메틸-캄프토테신, 7-p-페닐벤질옥시이미노메틸-캄프토테신, 7-[2-(2,4-디플루오로페닐)-에톡시]이미노메틸캄프토테신, 7-(4-t-부틸벤질옥시)-이미노메틸캄프토테신, 7-(1-아다만틸옥시)-이미노메틸-캄프토테신, 7-(1-아다만틸메톡시)-이미노메틸캄프토테신, 7-(2-나프틸옥시)-이미노메틸-캄프토테신, 7-(9-안트릴메톡시)-이미노메틸-캄프토테신, 7-옥시라닐메톡시이미노메틸-캄프토테신, 7-(6-우라실)-메톡시-이미노메틸캄프토테신, 7-[2-(1-우라실)-에톡시]-이미노메틸-캄프토테신, 7-(4-피리딜)-메톡시이미노메틸-캄프토테신, 7-(2-티에닐)-메톡시이미노메틸-캄프토테신, 7-[(N-메틸)-4-피페리디닐]-메톡시이미노-메틸캄프토테신, 7-[2-(4-모폴리니닐]-에톡시]-이미노메틸캄프토테신, 7-(벤조일옥시이미노메틸)-캄프토테신, 7-[(1-하이드록시이미노)-2-페닐에틸)-캄프토테신, 7-ter-부틸옥시-이미노메틸-캄프토테신 N-옥사이드, 7-메톡시이미노메틸캄프토테신 N-옥사이드, 이리노테칸 및 그의 활성 대사산물 SN-38로 이루어진 그룹으로부터 선택된 그 자체인 캄프토테신 유도체; PARP-1 억제제, 삽입성 DNA 제제 및 알킬화제로 이루어진 그룹으로부터 선택된 화학요법제 (b)로 이루어진 화학요법 조합물로서; 상기 조합물 내에, 각각의 성분 (a) 및 (b)는 서로로부터 개별적으로 제형되거나 단일 투약 형태로 제형되는 화학요법 조합물.